We are live on !
Find out more
Nextech Invest Portfolio holdings
AUM
$2.11B
Turnover
22.22%
1-Year Est. Return
413.84%
This Fund
S&P 500
This Quarter Est. Return
+67.86%
1 Year Est. Return
+413.84%
3 Year Est. Return
+982.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.11B
AUM Growth
+$686M
(+48%)
Cap. Flow
-$28.7M
Cap. Flow % of AUM
Cap. Flow %
-1.36%
Top 10 Holdings %
Top 10 Hldgs %
98.01%
Holding
18
New
1
Increased
3
Reduced
1
Closed
3
Avg Time Held
2.1
years
Top 10 Avg Time Held
1.9
years
Top 20 Avg Time Held
2.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$129M |
| 2 |
Relay Therapeutics
RLAY
|
+$18.1M |
| 3 |
Monte Rosa Therapeutics
GLUE
|
+$8.63M |
| 4 |
Arvinas
ARVN
|
+$5.44M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tango Therapeutics
TNGX
|
+$152M |
| 2 |
Tyra Biosciences
TYRA
|
+$16.6M |
| 3 |
Cullinan Oncology
CGEM
|
+$16.2M |
| 4 |
ARS Pharmaceuticals
SPRY
|
+$4.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Revolution Medicines
RVMD
$38.7B
| $1.42B | 67.55% |
7,601,087
| – | – |
2021 Q4
18 quarters
|
|
|
PBLS
2
Parabilis Medicines Inc
PBLS
$3.14B
| $128M | 6.06% |
+4,663,176
| New | +$129M |
2026 Q2
0 quarters
|
|
|
3
Relay Therapeutics
RLAY
$3.68B
| $127M | 6.02% |
6,776,506
+1,250,000
| +23% | +$18.1M |
2022 Q1
17 quarters
|
|
|
4
Tyra Biosciences
TYRA
$1.31B
| $114M | 5.39% |
3,553,585
-502,276
| -12% | -$16.6M |
2021 Q4
18 quarters
|
|
5
Alumis Inc
ALMS
$799M
| $100M | 4.73% |
3,540,998
| – | – |
2024 Q3
7 quarters
|
|
6
Oric Pharmaceuticals
ORIC
$1.28B
| $77.6M | 3.68% |
7,162,637
| – | – |
2023 Q2
12 quarters
|
|
7
Kymera Therapeutics
KYMR
$8.9B
| $32M | 1.52% |
278,896
| – | – |
2025 Q2
4 quarters
|
|
8
Zymeworks
ZYME
$1.83B
| $29.1M | 1.38% |
1,113,946
| – | – |
2024 Q3
7 quarters
|
|
|
9
Monte Rosa Therapeutics
GLUE
$850M
| $18.4M | 0.87% |
761,153
+456,916
| +150% | +$8.63M |
2025 Q4
2 quarters
|
|
|
10
Arvinas
ARVN
$464M
| $17.1M | 0.81% |
1,122,713
+583,319
| +108% | +$5.44M |
2021 Q4
18 quarters
|
|
11
CytomX Therapeutics
CTMX
$499M
| $16.7M | 0.79% |
4,449,932
| – | – |
2026 Q1
1 quarter
|
|
12
Silence Therapeutics
SLN
$1.22B
| $10.5M | 0.5% |
952,400
| – | – |
2024 Q1
9 quarters
|
|
13
Corvus Pharmaceuticals
CRVS
$808M
| $6.72M | 0.32% |
450,000
| – | – |
2026 Q1
1 quarter
|
|
14
Context Therapeutics
CNTX
$22.5M
| $4.11M | 0.2% |
7,419,355
| – | – |
2024 Q2
8 quarters
|
|
15
enGene Therapeutics
ENGN
$111M
| $4.02M | 0.19% |
2,324,943
| – | – |
2025 Q4
2 quarters
|
|
|
16
Cullinan Oncology
CGEM
$866M
| – | – |
-1,141,145
| Closed | -$16.2M | – |
|
|
17
ARS Pharmaceuticals
SPRY
$414M
| – | – |
-610,703
| Closed | -$4.9M | – |
|
|
18
Tango Therapeutics
TNGX
$3.83B
| – | – |
-7,266,081
| Closed | -$152M | – |
|
Similar funds
Nextech Invest's Q2 2026 Portfolio in Review
As of Q2 2026, Nextech Invest held 18 positions worth $2.11B, up 48% from $1.42B the previous quarter. Its ten largest holdings account for 98% of the portfolio.
Nextech Invest's Q2 2026 filing shows 1 new, 3 increased, 1 reduced and 3 closed positions. Its largest new stake was Parabilis Medicines Inc: 4,663,176 shares worth $128M. The largest sale was Tango Therapeutics, an estimated $152M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Nextech Invest's largest Q2 2026 buy was Parabilis Medicines Inc: 4,663,176 shares worth $128M.
- Nextech Invest added most to Relay Therapeutics in Q2 2026, an estimated $18.1M increase.
- Nextech Invest's biggest Q2 2026 reduction was Tyra Biosciences, cutting an estimated $16.6M.
- Nextech Invest fully exited Tango Therapeutics in Q2 2026, selling an estimated $152M.
- Nextech Invest's ten largest holdings make up 98% of its $2.11B portfolio in Q2 2026.
- Nextech Invest opened 1 new position and closed 3 in Q2 2026.
- Nextech Invest's portfolio value rose 48% quarter-over-quarter to $2.11B.
Based on Nextech Invest's 13F filing for Q2 2026, filed 14 Aug 2026.